Comanaging Cases of RR/MM in Patients Receiving CAR T
Panelists discuss how successful comanagement of CAR T-cell therapy cases requires close coordination between academic centers and community practices, with structured protocols for monitoring, communication, and patient handoffs, while addressing challenges in referral timing, resource allocation, and long-term follow-up care.
Video content above is prompted by the following:
- Describe your institution’s approach to the comanagement and comonitoring of patients receiving CAR T-cell therapy, particularly in the transition back to the community setting.
- Dr Abdallah to ask Dr Kort: Can you share any specific strategies or tools your institution utilizes to facilitate seamless transitions of care between the academic center and community practices for patients receiving CAR T-cell therapy?
- Dr Abdallah to ask Dr Mahmoudjafari: What are the most common challenges you have encountered in the CAR T referral process, and how have you addressed them at your institution?
- Dr Abdallah to ask Dr Mushtaq: What advice would you provide to community physicians regarding the appropriate timing and preparation for referring patients for CAR T therapy?
- Dr Abdallah to ask Dr Kort: Can you share any examples of successful collaborations between your academic center and community practices in the context of CAR T therapy for multiple myeloma?
- Dr Abdallah to ask Dr Mahmoudjafari: What are the most important lessons your institution has learned in the integration of CAR T therapy into the multiple myeloma treatment landscape?
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
